Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 2:01 pm Purchase | 2025-09-30 | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 8,601,189 13.900% | 2,248,120 (+35.39%) | Filing History |
| 2025-11-14 2:00 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 5,766,090 9.800% | -2,782,994 (-32.55%) | Filing History |
| 2025-11-10 2:33 pm Unchanged | 2025-11-09 | 13D | NEUPHORIA THERAPEUTICS INC NEUP | Lynx1 Capital Management LP | 875,328 26.500% | 0 (Unchanged) | Filing History |
| 2025-10-23 7:52 pm Sale | 2025-10-21 | 13D | NEUPHORIA THERAPEUTICS INC NEUP | Lynx1 Capital Management LP | 875,328 37.100% | -7,369,767 (-89.38%) | Filing History |
| 2025-10-10 6:53 pm Purchase | 2025-10-08 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 8,549,084 14.500% | 4,148,242 (+94.26%) | Filing History |
| 2025-08-14 07:06 am Purchase | 2025-06-30 | 13G | TSCAN THERAPEUTICS INC TCRX | Lynx1 Capital Management LP | 7,857,347 15.000% | 2,500,000 (+46.66%) | Filing History |
| 2025-08-14 06:58 am Purchase | 2025-06-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | Lynx1 Capital Management LP | 4,400,842 7.500% | 4,400,842 (New Position) | Filing History |
| 2025-02-14 09:02 am Purchase | 2024-12-31 | 13G | ALLOGENE THERAPEUTICS INC ALLO | Lynx1 Capital Management LP | 10,874,723 5.200% | 10,874,723 (New Position) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 462,848 15.000% | 41,500 (+9.85%) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | PRECISION BIOSCIENCES INC DTIL | Lynx1 Capital Management LP | 766,051 9.990% | 766,051 (New Position) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | TSCAN THERAPEUTICS INC TCRX | Lynx1 Capital Management LP | 5,357,347 10.900% | 132,747 (+2.54%) | Filing History |
| 2025-02-10 5:29 pm Purchase | 2025-02-06 | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 6,353,069 10.200% | 1,494,075 (+30.75%) | Filing History |
| 2025-02-10 5:22 pm Purchase | 2024-12-31 | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 4,858,994 9.300% | 663,100 (+15.80%) | Filing History |
| 2024-11-14 09:07 am Sale | 2024-09-30 | 13G | PIERIS PHARMACEUTICALS INC PIRS | Lynx1 Capital Management LP | 37,436 2.800% | -84,762 (-69.36%) | Filing History |
| 2024-11-14 09:05 am Purchase | 2024-09-30 | 13G | GH RESH PLC SHS GHRS | Lynx1 Capital Management LP | 4,195,894 8.100% | 1,201,835 (+40.14%) | Filing History |
| 2024-11-14 09:03 am Sale | 2024-09-30 | 13G | BIONOMICS LTD ADS BNOX | Lynx1 Capital Management LP | 8,245,095 3.200% | -4,119,480 (-33.32%) | Filing History |
| 2024-11-14 09:01 am Purchase | 2024-09-30 | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 6,880,527 9.900% | 3,746,131 (+119.52%) | Filing History |
| 2024-11-14 09:00 am Purchase | 2024-09-30 | 13G | STOKE THERAPEUTICS INC STOK | Lynx1 Capital Management LP | 5,187,191 9.900% | 2,230,273 (+75.43%) | Filing History |
| 2024-08-09 5:15 pm Purchase | 2024-08-07 | 13G | PASSAGE BIO INC PASG | Lynx1 Capital Management LP | 421,348 13.600% | 179,054 (+73.90%) | Filing History |
| 2024-04-01 7:23 pm Purchase | 2024-03-26 | 13G | IBIO INC PAR $0.001 IBIO | Lynx1 Capital Management LP | 878,492 9.990% | 878,492 (New Position) | Filing History |